Q-omics provides the consensus-scored FARSB profile across patient tissues and cancer cell-line models. FARSB expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, FARSB is differentially expressed in 18, with the highest sampling consensus in LUAD. Additionally, FARSB protein abundance shows 25,899 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight ACC, LUAD, and PDAC as cancer lineages where FARSB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FARSB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FARSB survival associations across molecular data types. FARSB RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7) and mass-spec protein abundance (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FARSB RNA expression–survival associations across cancer types. High FARSB expression shows unfavorable associations in ACC, LIHC, UVM, KIRP, LUAD and UCEC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for FARSB RNA expression.
This table summarizes FARSB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 18, while mass-spec protein shows differences in 9. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for FARSB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FARSB shows higher tumor expression in LUAD, KIRC, LIHC, COAD, LUSC and HNSC. The LUAD box plot shows higher FARSB RNA expression in tumor versus normal tissue (log2 FC = +1.064, t-test p < 0.001).
This table shows molecular features associated with FARSB in patient tissues and cancer cell lines. In patient samples, FARSB shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, FARSB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
